Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;19(2):377-385.
doi: 10.1208/s12248-016-0030-z. Epub 2017 Jan 12.

Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development

Laura I Salazar-Fontana  1 , Dharmesh D Desai  2 , Tarik A Khan  3 , Renuka C Pillutla  2 , Sandra Prior  4 , Radha Ramakrishnan  5   6 , Jennifer Schneider  6 , Alexandra Joseph  7
Affiliations
Review

Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development

Laura I Salazar-Fontana et al. AAPS J. 2017 Mar.

Abstract

All biotherapeutics have the potential to induce an immune response. This immunological response is complex and, in addition to antibody formation, involves T cell activation and innate immune responses that could contribute to adverse effects. Integrated immunogenicity data analysis is crucial to understanding the possible clinical consequences of anti-drug antibody (ADA) responses. Because patient- and product-related factors can influence the immunogenicity of a therapeutic protein, a risk-based approach is recommended and followed by most drug developers to provide insight over the potential harm of unwanted ADA responses. This paper examines mitigation strategies currently implemented and novel under investigation approaches used by drug developers. The review describes immunomodulatory regimens used in the clinic to mitigate deleterious ADA responses to replacement therapies for deficiency syndromes, such as hemophilia A and B, and high risk classical infantile Pompe patients (e.g., cyclophosphamide, methotrexate, rituximab); novel in silico and in vitro prediction tools used to select candidates based on their immunogenicity potential (e.g., anti-CD52 antibody primary sequence and IFN beta-1a formulation); in vitro generation of tolerogenic antigen-presenting cells (APCs) to reduce ADA responses to factor VIII and IX in murine models of hemophilia; and selection of novel delivery systems to reduce in vivo ADA responses to highly immunogenic biotherapeutics (e.g., asparaginase). We conclude that mitigation strategies should be considered early in development for biotherapeutics based on our knowledge of existing clinical data for biotherapeutics and the immune response involved in the generation of these ADAs.

Keywords: anti-drug antibodies; immune mitigation; immune prediction; therapeutic proteins; tolerance.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nat Rev Immunol. 2009 May;9(5):324-37 - PubMed
    1. J Biotechnol. 2010 Jul 1;148(1):38-45 - PubMed
    1. Am J Health Syst Pharm. 2012 Nov 15;69(22):1961-75 - PubMed
    1. Haemophilia. 2008 Jan;14 (1):44-9 - PubMed
    1. PLoS One. 2015 Sep 15;10(9):e0138123 - PubMed

Publication types

LinkOut - more resources